



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

September 2023
EMA/CHMP/185423/2010, Rev.3
Committee for Medicinal Products for Human Use (CHMP)

Guideline on clinical investigation of medicinal products in the treatment of depression

Draft

Draft agreed by CNSWP	1 September 2023
Adopted by CHMP for release for consultation	4 September 2023
Start of public consultation	15 September 2023
End of consultation (deadline for comments)	31 March 2024

This guideline replaces "Guidance on clinical investigation of medicinal products in the treatment of Depression" (EMA/CHMP/185423/2010, Rev. 2)

Comments should be provided using this [EUSurvey form](#). For any technical issues, please contact the [EUSurvey Support](#).

Keywords	<i>major depression, major depressive episode, partial response, treatment resistance, suicidal thoughts, suicidal behaviour, suicide, acute treatment, maintenance treatment, recurrence prevention</i>
-----------------	---



Guideline on clinical investigation of medicinal products in the treatment of depression

Table of contents

Executive summary	4
1. Introduction (background)	5
Major Depressive Disorder (MDD)	5
2. Scope.....	6
3. Legal basis and relevant guidelines	6
4. Specific considerations when developing products for the treatment of depression.....	7
4.1. Clinical Pharmacology Studies	7
4.1.1. Pharmacodynamics.....	7
4.1.2. Pharmacokinetics	7
4.1.3. Interaction studies.....	7
4.2. Assessment of Therapeutic Efficacy.....	8
4.2.1. Target of estimation in depression	8
4.2.2. Placebo effect and strategies to address high placebo response.....	9
4.2.3. Investigation of relapse and recurrence	10
4.2.4. Study population	11
4.2.5. Extrapolations.....	11
4.3. Methodological features	11
4.3.1. Efficacy endpoints	11
4.3.2. Study design	12
4.3.2.1. Short-term trials.....	12
4.3.2.2. Long-term trials	13
4.3.2.3. Rapid acting antidepressants (RAAD).....	13
4.3.2.4. Psychedelics	14
4.3.3. Statistical considerations	15
4.4. Specific claims.....	16
4.4.1. Treatment resistance and partial response	16
4.4.1.1. Trial design in TRD and partial response.....	16
4.4.2. Specific domains in MDD	17
4.4.2.1. Improvement in cognitive function	17
4.4.3. Depression with specifiers.....	18
4.5. Special Populations.....	18
4.5.1. Elderly patients.....	18
4.5.2. Children and adolescents.....	19
4.5.3. Gender issues/differences.....	20
4.6. Safety Evaluation	20
4.6.1. Specific adverse events to be monitored	21
4.6.1.1. Psychiatric adverse events	21
4.6.1.2. Adverse effects on cognitive functioning.....	21

56 4.6.1.3. Overdose and suicide 21

57 4.6.1.4. Metabolic risk factors 21

58 4.6.1.5. Haematological adverse events..... 22

59 4.6.1.6. Endocrinological adverse events..... 22

60 4.6.1.7. Cardiovascular adverse events..... 22

61 4.6.1.8. Sexual dysfunction..... 22

62 4.6.1.9. Extrapyrarnidal symptoms (EPS) 22

63 4.6.1.10. Serotonin syndrome / Neuroleptic malignant syndrome 22

64 4.6.1.11. Rebound / withdrawal phenomena / dependence 22

65 4.6.1.12. Long-term safety 23

66 4.6.1.13. Elderly patients..... 23

67 4.6.1.14. Children and adolescence..... 23

68 **5. References 23**

69 **Definitions 31**

70 **Abbreviations 32**

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Executive summary

The present document should be considered as general guidance on the development of medicinal products for acute and long-term treatment of Major Depressive Disorder (MDD). It updates and replaces the previous guideline (EMA/CHMP/185423/2010 Rev. 2). The main focus is on major depressive episodes that occur in the context of MDD. Bipolar and related disorders are separated from the depressive disorders in DSM-5 and possible extrapolations in alignment with the bipolar guidance document will also be addressed.

Up to two thirds of MDD patients do not achieve remission following an initial adequate trial of antidepressant therapy.

Despite many approved antidepressants there is a need for new medicinal products with better efficacy (e.g. faster onset of action, higher rates of response and remission) and improved safety profile.

The main requirements for the development of medicinal products for the treatment of major depression are reviewed and reconfirmed based on experience with recent clinical development programs. **The typical design to demonstrate efficacy and safety of an antidepressant remains a randomized, double-blind, placebo controlled, parallel group study comparing change in the primary endpoint. The results must be robust and clinically meaningful.** This requires besides statistically significant results the incorporation of rates of response/remission to adequately assess clinical relevance. **It has to be shown that the initial response to treatment is maintained in at least one study following an adequate design.** The emergence of new antidepressants with rapid onset of effect and the repurposing of psychedelics require separate design strategies. The requirements for clinical trials in partial and non-responders (i.e. treatment resistant depression) with MDD are revisited. Nearly 70% of patients with major depressive disorder (MDD) experience residual symptoms with first line standard of care. These may include anxiety, impaired cognition, fatigue, sleep disturbance and anhedonia.

To support a separate claim in specific domains or symptom clusters within MDD (e.g. cognitive dysfunction) justification for the therapeutic rationale will be needed and specific studies should be performed.

The update specifically addresses:

- Several aspects for trial designs in difficult to treat patients (partial responders or non-responders to treatment) including the definition and identification of those patients, the role of augmentation and combination strategies
- Clinical development requirements for new rapid acting therapies
- Issues to consider for the development of psychedelic medications and the new paradigm of psychedelic associated psychotherapy in the field of MDD
- Clinical development requirements to target sub-domains of depression
- Requirements for clinical trials in children and adolescents and possible extrapolation from adult data
- Gender and drug metabolism differences in patient populations

The need to monitor the degree of suicidal thoughts and behaviour and their change (improvement or worsening) with antidepressant therapy by use of validated instruments is confirmed.

1. Introduction (background)

Major Depressive Disorder (MDD)

MDD is one of the most common and disabling psychiatric disorders and the fourth leading cause of global disease burden. An estimated 3.8% of the population worldwide is affected by MDD, including 5.0% of adults (4% among men and 6% among women), and 5.7% of adults older than 60 years. Approximately 280 million people in the world have depression. Depression is about 50% more common among women than among men. Worldwide, more than 10% of pregnant women and women who have just given birth experience depression. MDD is not a benign disorder. More than 700 000 people die due to suicide every year (World Health Organization, Depression Fact Sheet, 2023). For preschool children MDD is very rare (point prevalence is thought to be 0.5%), in adolescents the prevalence is estimated to be approximately 8%. Meta-analytic analyses suggest a higher prevalence of MDD in adolescents than in the general global population, but the paucity of youth-specific epidemiologic studies of MDD across regions warrants further investigation. Signs and symptoms of MDD are similar to the adult population; however, differential diagnosis in this population is difficult particularly with dysthymic disorder or bipolar disorder. Studies on efficacy and safety of antidepressants in children and adolescents are necessary (section 4.5.2).

Depressive disorders are classified in various classification systems, e.g., currently DSM-5 and ICD-11. Both classifications are built principally on severity, features of the current episode, patterns of disease expression over time, as well as persistence and recurrence.

The detection of MDD requires the presence of depressed mood or loss of interest and pleasure in activities accompanied by at least two (ICD-11) or five symptoms of depression (DSM-5). These core symptoms may vary from patient to patient, however, they are typically seen for much of the day, almost always every day for at least two weeks and are associated with relevant psychological distress and considerable impairment in social, occupational, or other important areas of functioning.

A shift in the definition of MDD in DSM-5 to distinguish it from other disorders e.g. bipolar and anxiety disorder has been noted. Despite the common features of Major Depressive Disorder (unipolar) with Bipolar Disorder (BD), there are differences in duration, timing, phenomenology, family history and genetics (section 4.2.5.).

Despite the many treatment options currently available for MDD, up to 50% of patients do not adequately respond to the first antidepressant prescribed and up to two thirds do not achieve remission, even if there is good compliance and the treatment has been taken for a sufficient length of time at an adequate dosage.

In clinical practice, treatment algorithms have been established including re-evaluation of the initial diagnosis and, when no correctable cause is found, optimization of the initial regimen or switching to other antidepressants or augmentation strategies (e.g. combination therapy, lithium and other mood stabilizers, atypical antipsychotics, etc.) or even monotherapy with second generation antipsychotics have been considered within the psychopharmacologic options. However, treatment approaches are not standardised. The recent approval of a treatment for TRD in an add-on setting with conventional SSRIs or SNRIs after at least two treatment failures has established adjunctive treatment trials as a valid approach for TRD (section 4.4.1.).

In many clinical treatment guidelines electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS) are options for patients suffering from severe TRD. However, non-medicinal approaches and non-pharmacological interventions are not within the scope of this guideline. Notwithstanding the availability of many compounds with established efficacy and safety there

is a high need for new antidepressants. Recent studies have stimulated new basic research in the antidepressants field and have identified new neural signalling circuits in antidepressant response and novel antidepressant mechanism (section 4.4.3.). **Conventional antidepressants usually require 4 to 6 weeks to exert their therapeutic effects.** Rapid acting antidepressants (RAADs) can have different pharmacokinetic and pharmacodynamic characteristics and may require different studies (section 4.3.2.3.). Psychedelics are currently being recognised in psychiatry as potential treatment options to treat various medical conditions including depression. Psychedelic-assisted psychotherapy faces several challenges mainly related to standardisation, training, monitoring and safety that need to be addressed in specific study designs (section 4.3.2.4.).

It has been shown that many patients without adequate treatment suffer from a tendency of higher frequency of major depressive episodes together with an increased severity. Therefore, pharmaceutical companies are encouraged to foster development of new antidepressants and not only focus on the treatment of acute symptoms and maintenance of the effect during the index episode, but explore also the potential of their compounds in the prevention of new episodes called recurrence prevention. However, prevention of a new episode (recurrence prevention) is not a mandatory part of a registration package for treatment of episodes of MDD, but is considered as an additional claim (section 4.2.3.).

2. Scope

This guideline focuses on antidepressant products developed specifically for major depressive disorder. Recent experience with approval procedures, PRIME allocations and scientific advices at EMA as well as new results in basic science and clinical guidelines reflecting current medical practice have been taken into consideration with the revision of the guidance document. Specific methodological issues as well as efficacy and safety issues regarding special populations like children and adolescents, young adults and older people have been addressed.

After the release of DSM-5 and ICD-11 the implementation of more dimensional aspects has consequences for the definitions of mood disorders as given in this guideline. With the transition of DSM-IV into DSM-5, bipolar and related disorders have been separated from depressive disorders, and BD II is no longer considered a milder form of BD I.

Symptoms of major depressive episodes occurring in comorbidity with other psychiatric disorders or with somatic disorders like Parkinson's disease, Alzheimer's disease, cerebrovascular disorders, cancer and chronic pain syndromes are not in the focus of this guideline.

3. Legal basis and relevant guidelines

This guideline has to be read in conjunction with the introduction and general principles (4) and part I and II of the Annex I to Directive 2001/83 as amended. Further is referred to the EMA and ICH guidelines on pharmaceutical development, PK/PD topics, clinical trial design, special populations including the elderly and paediatric population:

<https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines>

Among them those of specific interest for depression are:

CPMP/EWP/567/98 Note for guidance on clinical investigation of medicinal products for the treatment and prevention of bipolar disorder

ICH E11 (R1) Guideline on Clinical Investigation of Medicinal Products in the Paediatric Population

214 ICH E11A on paediatric extrapolation
215 ICH E7 Studies in Support of Special Populations: Geriatrics, including Questions and Answers
216
217 EMEA/CHMP/SWP/94227/2004 Guideline on the non-clinical investigation of the dependence potential
218 of medicinal products.

219 **4. Specific considerations when developing products for the** 220 **treatment of depression**

221 **4.1. Clinical Pharmacology Studies**

222 **4.1.1. Pharmacodynamics**

223 MDD is a psychiatric syndrome, which is associated with subtle cellular and molecular alterations in a
224 complex neural network. Animal models can be used for screening of antidepressant medicinal
225 products, however, direct transfer to human models is not possible. **In humans with MDD brain**
226 **structural and functional findings (e.g. activation studies using magnet resonance or emission**
227 **tomography, electrophysiological studies, neuroendocrine circuits, etc.) as well as genomic, proteomic**
228 **and metabolomic measures have been studied, but are incompletely understood and therefore yet still**
229 **of limited value.** So, a variety of tests can be performed, but there is no specific model in humans for
230 MDD. Studies on cognition, reaction time and sleep may be helpful to characterize the safety profile of
231 an antidepressant and should be considered based on pharmacological profile/MOA and evolving
232 tolerability profile of the proposed product.

233 Novel mechanisms of actions and novel pathways associated with quicker onset of action should be
234 specifically investigated to provide the appropriate support for the clinical efficacy.

235 For specific domains, it is expected that appropriate preclinical studies (e.g. in vitro and receptor
236 binding studies) should be able to support the mechanism of action and the positive effects in the
237 domains.

238 **4.1.2. Pharmacokinetics**

239 Studies should be performed to characterise the pharmacokinetics of the new medicinal product (see
240 guideline on pharmacokinetic studies in man) and where possible this information should be used to
241 study the relationship between dose, exposure and response. Population PK analyses may be used to
242 investigate pertinent covariates e.g. weight, age, sex (gender), healthy vs patient population,
243 concomitant medications, etc. that may influence the pharmacokinetics of the drug. The choice of dose
244 for the clinical program should be adequately justified.

245 **4.1.3. Interaction studies**

246 In general, the guideline on drug interactions should be followed to investigate possible
247 pharmacokinetic interactions with other drugs and food. Interactions with alcohol and other relevant
248 CNS active compounds should be investigated. If appropriate, pharmacokinetic studies in patients
249 with hepatic and/or renal impairment should be performed (see CPMP/EWP/560/95/Rev. 1 Corr. 2**).

4.2. Assessment of Therapeutic Efficacy

It is acknowledged that there are a number of methodological issues being discussed in the scientific community when conducting clinical trials in depression, including the potential reasons for an increased placebo effect/response and proposals to address this issue (section 4.2.2.).

Clinical studies should provide unambiguous evidence of the antidepressant efficacy and of the effective dose or dose range. **It is generally preferred to establish the dose-response relationship in a phase II multiple arm parallel fixed dose study in order to maximise confidence that the doses(s) studied in phase III are optimal.** The minimum effective dose and the dose at which most efficacy is achieved should be established.

Due to variable observed treatment effects in MDD studies, usually at least two pivotal short-term studies are expected. A relapse prevention study should also be conducted (section 4.2.3.).

In depression, comparisons between a test medicinal product and reference substances are difficult to interpret since there is **a high and variable placebo response in depression. Actually, in about one-third to two-third of the trials, in which an active control is used as a third arm, the effect of the active control could not be distinguished from that of placebo.** As the effect rate in a specific trial is thus uncertain, a non-inferiority margin cannot be determined and a two-arm non-inferiority trial is not an option, as the sole basis for demonstrating efficacy. Hence, randomised, double blind, placebo controlled trials are the gold standard to permit adequate evaluation of short-term efficacy. A two-arm trial establishing superiority of the test product over active comparator may be considered acceptable as one of two required pivotal short-term studies to establish an antidepressant effect of the new test product, but does not necessarily allow claiming better efficacy than the comparator.

For final benefit-risk assessment the whole data package of a development program will be taken into consideration.

Results should be discussed in terms of both clinical relevance and statistical significance, and the effect should be shown to be robust and insensitive to the analysis used. When an effect is quantified in terms of change from baseline to end of treatment using a validated measurement tool, this effect has to be addressed also as rates of responders and remitters. It should be noted that the relevance of the effect is the primary basis for the benefit/risk assessment. An adequately weighted meta-analysis of efficacy across all clinical studies may improve the precision of the pre-defined responder-based estimates of clinical efficacy. However, the statistical methods to be used and the clinical studies to be included should be justified as these may influence the estimates of the effect size.

4.2.1. Target of estimation in depression

The scientific question(s) of interest, i.e. what the trial seeks to address, and consequently the target(s) of estimation (estimand) should be clearly specified. Trial planning, design, conduct, analysis, and interpretation must be aligned with the estimand. Reference is made to ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials (EMA/CHMP/ICH/436221/2017).

Relevance and (expected) frequency of intercurrent events may differ between different therapeutic settings and consequently influence the definition of a relevant (primary) estimand. Different estimands may be warranted depending on the type of treatment such as monotherapy, add-on treatment or rapid acting antidepressants as well as depending on the therapeutic goal: treatment of acute symptoms in current (index) episode, maintenance of effect during current episode (relapse prevention) and prevention of new episodes (recurrence prevention) with long-term treatment (see also section 4.2.3.).

With a considerable number of alternative treatments available in the MDD setting, relevant intercurrent events to be considered include, but are not limited to, treatment discontinuation and changes in medication such as use of alternative anti-depressants or other medications and changes in background therapy (e.g. psychotherapy, anxiolytic medication, hypnotic medication). In addition, depending on the population selected, death due to committed suicide might require incorporation into the estimand definition.

Irrespective of the setting and unless an alternative strategy is duly justified, 'treatment discontinuation' should be handled with a treatment policy strategy addressing the treatment effect regardless of discontinuing treatment. Similarly, a treatment policy strategy is relevant for changes in background therapies, which is equivalent to considering them as part of the treatment regimen of interest.

Handling the use of alternative anti-depressants that are not considered part of the treatment regimen of interest (i.e. therapies that could not be co-administered with the investigational treatment) is challenging and discussions on the most appropriate estimand are still ongoing. A treatment policy strategy could be appropriate, but a hypothetical strategy, in which alternative medication is assumed not to have been an option, might be more relevant. Still, the downside of this hypothetical strategy is that a theoretical treatment effect – not existing in the real world – is estimated, as alternative treatments are available in real life. Furthermore, the use of alternative medications generally follows patients' discontinuation from the treatment regimen of interest, and appropriate methods should be used to handle these co-occurring events with different strategies. As another option, considering the use of alternative medications as failure, they could be incorporated in the endpoint with a composite strategy (e.g. in a dichotomized responder definition). However, if this strategy is implemented through dichotomization, the loss of information would suggest that this estimand should rather be considered as a secondary estimand, at least for short term trials. Additionally, the treatment effect assuming all patients adhered to the treatment regimen (i.e. hypothetical strategy for both intercurrent events 'treatment discontinuation' and 'changes in medications not considered part of the treatment regimen') could be of interest as a secondary estimand only. This may be included merely as a means to compare effect estimates to past trials.

For binary or time to event endpoints such as relapse instead of or in addition to the strategies discussed above, it may be warranted to apply a composite strategy for the (primary) estimand definition, e.g. the intercurrent events such as treatment discontinuation or use of alternative medications could be integrated into a composite variable with relapse. In any case, intercurrent events that are included as part of a composite endpoint definition need to be clinically relevant in themselves.

Overall, the choice of estimand and the aligned methods of estimators (section 4.3.3.) are still areas of ongoing discussion and research. Sponsors are encouraged to discuss the estimand and aligned trial design and method of estimation (analytical approach) at Scientific Advice or Protocol Assistance.

4.2.2. Placebo effect and strategies to address high placebo response

A high placebo effect has been observed in trials that were submitted for approval in MDD. Several factors are thought to contribute to high placebo response and applicants should control and account for these factors during the process of screening, population selection and conduct of the trial. Of note, **applicants should justify the representativeness of the population, which should be comparable to the clinical population for which an indication is sought.**

Enrichment strategies with a placebo run-in are only acceptable in phase 2 but not for phase 3 studies, since the clinical validity of the studies may be affected (section 4.3.2.). For such studies, further discussion on the relevant estimand may be required.

Taking into consideration the above, randomised double-blind comparisons versus placebo in the whole population are needed to allow adequate evaluation of efficacy.

Comparison to a placebo treatment is also of value for distinguishing disease manifestations from adverse reactions of the medicinal product.

Precautions to minimise the impact of the use of placebo on the potential deterioration of the patients' condition should be taken, e.g., by limiting the duration of the study (section 4.3.2.).

4.2.3. Investigation of relapse and recurrence

Depressive symptoms are occurring in a heterogeneous group of patients and there is a large variance in the natural course of MDD. In the literature a distinction is made between treatments in the acute phase, the continuation phase and if required, the maintenance phase.

The aim of the demonstration of antidepressant efficacy is to observe improvement in a generally accepted scale for the acute phase, corresponding to the current (index) depressive episode. Usually a response criterion of 50 % or more is applied to define treatment response (see also section 4.4.1). The next step of the clinical programme should be maintenance of the initial anti-depressive effect, throughout the current depressive episode (relapse prevention). The duration of the continuation phase is usually set at about 6 months, to correspond with the average duration of an episode of depression. In any individual, however, it should be noted that the duration of an episode varies considerably and may be more (or less) than 6 months. As this might affect the interpretation of the results, the 6 months cut-off point is not used for regulatory purposes. Instead, the guideline focuses on showing effect during the index episode and/or prevention of the next episode.

The definitions of relapse prevention and recurrence prevention assume that symptomatic improvement occurs before resolution of the underlying pathophysiology and that the risk of relapse only decreases as the pathophysiology continues to resolve. In practice, the prevention of relapse is usually seen in the context of short-term treatment (and within the current depressive episode), whilst the prevention of recurrence is seen in the frame of indefinite continuation.

For authorisation it should be shown that a short-term effect can be maintained during the current (index) episode (relapse prevention) (section 4.3.2.).

Prevention of the next episode(s) or recurrence prevention is a worthwhile treatment goal. It is encouraged to evaluate this in specific studies (section 1.1.). Patients in full remission should be randomized to test product or placebo. Study duration will be dependent on the frequency of episodes in the study population and should be justified accordingly. Recurrence should be prespecified as a depressive episode that fulfils current DSM-5 criteria and a certain degree of severity on a validated rating scale. In non-bipolar patients, definitive comparisons of the test substance should be performed versus a placebo. For prevention in bipolar patients, the relevant guideline should be consulted.

For a given patient in the everyday clinical practice, the duration of treatment depends on the rate of his/her recurrences. Patients with a history of higher frequency depressive episodes should be included in the recurrence prevention investigation and the recent recurrence rate should be taken into account when planning the duration and power of the study.

4.2.4. Study population

Major depressive disorder (MDD) should be classified according to an internationally acknowledged classification system, preferably DSM-5 or ICD-11, using the diagnostic criteria therein. The same classification system should be used for the whole development of the medicinal product. A rating scale alone is insufficient and is not equivalent to a diagnosis.

Further descriptive parameters, like severity of the episode, as well as a detailed history, e.g., duration of the depression and of the index episode, number of episodes per time interval, previous treatment outcome, should also be documented.

Episodes of MDD can be classified as mild, moderate and severe. Clinical trials will usually recruit patients, who are moderately or severely ill, as it is difficult to demonstrate an effect in mildly ill patients. Demonstration of an acceptable benefit/risk ratio in moderately ill patients will be considered sufficient for a registration package to get a general license for "Treatment of Episodes of Major Depression" in the context of MDD. However, a sufficient number of patients with severe depression should be included in the clinical development program.

In addition, cut-off scores, based on an appropriate scale may be used as inclusion criteria. It is highly desirable that the study population is homogeneous with respect to the indication for the dose finding and pivotal studies (section 4.2.2.).

Though some of the earlier studies may be done in hospitalised patients, the majority of the database should be in out-patients for better generalizability of the study results.

4.2.5. Extrapolations

Patients included in the trials will be diagnosed as having MDD using accepted diagnostic criteria, DSM-5 or ICD-11. However, depressive symptoms are also seen in other psychiatric disorders or other types of depression. If such specific claims are strived for, additional studies to the classical development program for major depression should be provided.

As already mentioned in the introduction, a major depressive episode may also occur in the framework of bipolar and related disorders. In general the development of a product in this patient group will be the same as for unipolar depression. Extrapolation of short term and maintenance of efficacy in adults from unipolar depression to bipolar depression need to be considered on a case by case basis. Some specific issues, like duration of the episodes, switching rates and population selection and safety data, are addressed in the guideline on bipolar disorder.

For studies required in paediatric patients and possible extrapolations reference is made to section 4.5.2.

4.3. Methodological features

4.3.1. Efficacy endpoints

The choice of rating scales should be justified on the basis of test quality criteria (reliability, validity) and the sensitivity to change should be known. For the assessment of improvement specifically developed rating instruments are necessary.

Acceptable scales to determine symptomatic improvement include the Hamilton Rating Scale of Depression, preferably the 17 item scale, and the Montgomery-Asberg Depression Rating Scale, however other validated scales might be acceptable as well. For rapid acting antidepressants it is

anticipated that specific scales, other than the most commonly used MADRS, will be developed and validated, in order to be able to fully capture the rapid onset of effect. The protocol should indicate which scale is used as primary assessment tool.

In addition, changes in global assessment (e.g. Clinical Global Impression assessment scale) or in social functioning may be used as a key secondary endpoint as long as the assessment tools are validated.

Investigators should be properly trained in evaluating the patient. **Inter-rater reliability scores** (e.g. by using kappa statistics) should be documented for each investigator in advance and if necessary, during the study, both with regard to the diagnosis and to rating scales used for efficacy and safety, where relevant.

Since the patients' perspective on the relative importance of symptoms of their disorder is relevant self-rated symptoms scales can also be used and the development of new patient-reported outcomes (PROs) is encouraged. It is noted that these outcomes can only be supplementary and are recommended as secondary endpoints in clinical trials.

Despite recent advances in the field, specific biomarkers have not yet been established in MDD. It is considered essential that sufficient data are collected before any biomarker can be used for prognostic or predictive purposes or is sufficiently sensitive to changes in the course of the condition/disorder. Applicants are encouraged to seek scientific advice/qualification procedure to discuss adequacy of the proposed biomarker.

4.3.2. Study design

Generally, two randomised, double blind, placebo controlled trials are needed to allow adequate evaluation of short-term efficacy. Maintenance of effect should be shown in a long-term study (section 4.2.). The following general design aspects should be taken into account for trial planning.

Use of a placebo run-in period (single- or double-blind) and potential subsequent patient selection is considered problematic with regard to the generalisability of the results to the population treated in clinical practice, since patients included in the trials may not correspond to the target population. With respect to placebo response reference is made to section 4.2.2.

If a constant anxiolytic or hypnotic medication cannot be avoided, stratified randomization may be useful to help assess consistency of the treatment effect in each relevant subgroup.

A trial-specific, standardised psychotherapy, psycho-education, support or counselling may be given as supplementary treatment, though it may enhance the response in both treatment groups, but it should be prospectively defined in the protocol. It should be documented in detail and its influence on treatment effect should be analysed.

For any trial, potential centre effects should be carefully evaluated.

4.3.2.1. Short-term trials

Depending on the mechanism of action, pivotal trials should be long-enough to demonstrate a treatment effect.

The duration of these trials usually is around 6 weeks (at least 4 weeks have been needed to clearly separate active treatment from placebo, in some programmes 8 weeks have been studied).

Improvement should be documented as the difference between baseline and post-treatment score in signs and/or symptoms but should also be expressed as the proportion of responders or remitters. **In MDD a 50% improvement of a patient on a usual rating scale is accepted as a clinically relevant response.** Other definitions of responder may be used, e.g. other grades of response or proportion of patients with full remission. Criteria for response and remission must be pre-specified and justified in the study protocol.

4.3.2.2. Long-term trials

Due to the character of the disorder, longer trials are necessary to demonstrate that the acute effect is maintained during an episode (relapse prevention). For this, a randomised withdrawal study is the preferred design. In this design, stable responders to treatment with the test product are (re-) randomised to test product or placebo. In the first period, the test product is usually given open-label, uncontrolled. The duration of either treatment phase is hugely variable in the literature. It will depend among others on the type of patients included and on the time of inclusion. **The optimal duration is not known at the moment, but a duration of e.g. 6 to 12 weeks for the first period appears acceptable, whereas the period after (re-) randomisation usually has a duration of 6 months. The duration of 6 months is not strictly necessary when a time to event approach is chosen.** For such study, the protocol must include specific measures to prevent complication of the disease (especially risk of suicide), like close monitoring and the possibility to use rescue medication or to switch deteriorating patients to appropriate treatment. Special attention is needed to distinguish relapse from withdrawal symptoms, when medication is stopped or tapered off in such a study.

Generally, **a solely placebo-controlled extension study is not recommended**, as there is a risk, that the results will be ambiguous with regard to the question of maintenance of effect. However, in particular cases (e.g. special mechanism of action, populations with very low relapse rate, etc.) this might be an alternative approach to generate long-term efficacy and safety data, but should be justified by the applicant.

In randomised withdrawal trials, efficacy usually is expressed as rate of patients worsening (relapsing) and/or time to this event. Both efficacy criteria are of interest and should be submitted. The choice of one of them as primary and the relevance in clinical terms will depend on the target population which is selected based on pre-defined criteria and will need to be justified.

Worsening or relapse has to be defined in the protocol. Usually, a clinically relevant increase in symptoms scored on a validated rating scale is used. In long-term maintenance trials impact of intercurrent events may be higher as compared to short-term trials. Furthermore, for randomized withdrawal trials, additional considerations on the target population are required. Usually, patients responding to short-term active treatment (pre-defined response criteria) are recruited and this restriction of the population needs to be reflected in the estimand definition for the withdrawal part.

4.3.2.3. Rapid acting antidepressants (RAAD)

For antidepressants with a rapid onset of effect, both rapid efficacy and sustainability of effect will have to be characterised keeping in mind the natural course of a depressive episode. Double blind, randomised, parallel group, placebo-controlled clinical trials are required, as is the case with conventional antidepressants. Depending on the mechanism of action, an earlier efficacy endpoint could be appropriate but the acute onset of action should be clearly predefined and measured accordingly with a validated scale. Scientific advice is recommended if a rapid onset of effect indication is pursued to achieve agreement on the most appropriate measurement timepoints and trial duration to establish efficacy and safety. Rapid acting antidepressants may be studied as monotherapy

and/or add-on treatment. The following treatment situations can be foreseen a) as monotherapy, where the rapid acting antidepressant is administered alone initiating therapy or replacing a conventional antidepressant b) initiation of treatment with a RAAD followed by maintenance treatment with a conventional antidepressant agent in a sequential way and c) maintaining the conventional antidepressant and initiate treatment with a RAAD followed by a maintenance dose of RAAD as add-on approach. Each situation requires a different study design. In any case durability of effect beyond the initial treatment response should be characterized.

4.3.2.4. Psychedelics

Psychedelics include various psychoactive compounds of different chemical classes such as classical hallucinogens that act as 5-HT_{2A} agonists (e.g. psilocybin, LSD, DMT, mescaline) and “atypical” psychedelics including dissociative anaesthetics (e.g. ketamine, esketamine) and entactogens (e.g. MDMA). Psychedelics alter perception, energy levels, mood and affect numerous cognitive processes via different mechanisms of action that remain to be established in the context of therapeutic use. They can however also induce anxiety and other psychiatric adverse events including suicidal ideation and behaviour (section 4.6.1.). These as well as cardiovascular effects require careful monitoring and further investigations.

Several studies with psychedelics in the field of depression are currently ongoing. As with all other antidepressants, to establish a positive benefit/risk randomized, double-blind placebo-controlled short-term trials are needed, as well as trials to determine the maintenance of effect. Due to the safety profile and challenging study setup and execution, it is recommended to start development in a more severely affected population, such as patients with treatment resistant depression (section 4.4.1.). The psychoactive effects of currently investigated psychedelic agents present several challenges for the design, conduct, and interpretation of clinical trials:

- placebo and/or comparator. Due to the totally different function of the brain under psychedelic substances the choice of appropriate comparator while maintaining the blinding can be challenging.
- expectancy and unblinding. Positive expectancy might lead to overestimation bias while disappointment with treatment (negative expectancy) might lead to symptom worsening or safety issues (nocebo effect). Different strategies such as low dose or active placebo, i.e. alternative substances with a distinct mechanism of action but with a similar psychoactive effect have been considered to make it more difficult to guess the treatment arm. The use of independent and blinded external raters could help to mitigate the effects of unblinding and expectancy.
- dosing. As in every application, the justification for the adequate therapeutic dose is an important aspect of the MA submission dossier. The dose-effect relationship needs to be characterised. In particular, the relationship between characteristics of the acute psychedelic experience and clinical improvement, as well as the need for individualised dosing due to inter-individual variability in drug metabolism, age, sex, or personality should be investigated.
- maintenance of effect. Endurance of effect needs to be demonstrated and need for recurrent dosing addressed (see section 4.3.). The experience and the information available about the sustainability of the action and the long-term effects of psychedelics are very limited.
- safety. The ability to change the perception of reality can have unknown implications for depressed patients (anxiety with derealisation, negative trips). Although classical serotonergic psychedelics do not appear to show potential for addiction this cannot be ruled out for all

products, depending on the mechanism of action. Headaches, elevated blood pressure, tachycardia and suicidality have also been reported with the use of psychedelics. That is why psychedelics need to be administered in a controlled environment. Drug-drug interactions in case of regular co-administration need to be characterised. Also, long half-life psychedelics may require long surveillance which can be burdensome for patients, physicians and health care systems.

- psychotherapy. The monotherapy setting with psychedelics alone may not be applicable or feasible. The application of psychedelics is usually embedded in a non-directive psychological support. Trials need to be able to demonstrate that the effect of the psychedelic assisted therapy is not due to the psychotherapy alone. The framework of operation (protocol) as well as preparatory and post-dose integration sessions and whether this needs to be adapted to the type of psychedelic need to be clearly defined. Type, length and frequency of psychotherapy and training need to be standardised to the maximum possible effect, despite ethnic and cultural differences. Extrapolation from the trial setting to clinical practise or the plan to provide specific training to therapists needs to be addressed.

Due to the diversity of compounds and actions of psychedelics, potential safety issues and the need for a case-by-case approach, applicants are encouraged to seek scientific advice, prior to initiating their clinical development program.

4.3.3. Statistical considerations

Generally, efforts should be made to collect all relevant data for the primary and important other estimands (e.g. follow-up regardless of intercurrent events) to minimize the need to rely on untestable assumptions in the analysis and interpretation of the trial results.

Still, handling of missing data is of particular concern, as a relevant amount of missing data (often differential across treatment arms) has to be expected based on trial results from the past.

Furthermore, some data points after occurrence of an intercurrent event may need to be regarded as 'missing' (or at least not used as they are) for estimation of a specific estimand, despite the fact that data were actually collected after the intercurrent event and may be relevant for other estimands.

When missing data follows treatment discontinuation, the analysis should not implicitly assume that all the benefit from treatment is retained. Hence, methods based on the missing-at-random assumption are not acceptable if (primarily) based on data collected while on treatment - for estimation of the treatment effect regardless of treatment discontinuation. This similarly applies when targeting the effect had patients not used alternative anti-depressants (hypothetical strategy), as patients likely discontinued treatment prior to changing to an alternative. Hence, the disease course after the intercurrent event has to be modelled and/or imputed and may rather reflect treatment failure.

Multiple-imputation-based approaches can be considered for analysis as they provide sufficient flexibility for estimation (e.g. missing data may be handled differently for different intercurrent events incorporated in the targeted estimand). Missing data for patients discontinuing treatment could be imputed based on data of patients that were followed beyond treatment discontinuation in a retrieved-dropout approach. Alternatively, placebo-based imputations (with a justified assumption on the amount of benefit retained, if any) could be considered. Similar considerations apply for estimation of the effect regardless of treatment changes (treatment policy strategy for 'change in background treatment'). When estimating the effect had no alternative treatment been initiated after treatment discontinuation, retrieved dropout or placebo-based imputations could be an acceptable approach. However, different handling of missing data may be warranted as patients who initiate an alternative treatment may relevantly differ from patients simply discontinuing treatment.

In any case, assumptions underlying the primary analysis should be examined through pre-specified and justified sensitivity analysis (e.g. tipping point analyses) addressing the same estimand. . Analyses estimating other estimands can also assist in the interpretation of trial data and may supplement benefit-risk assessment.

4.4. Specific claims

4.4.1. Treatment resistance and partial response

Treatment resistance in depression develops in a continuum with progressively higher resistance depending on the number and nature of interventions failed (see section 1.3). Nevertheless, the distinction between partial response and TRD is still valid for indication claims and the type of patients to be included in clinical trials. The classical distinction between add-on or augmentation trials in partial responders versus monotherapy trials for non-responders however, is no longer valid since efficacy for TRD has been shown in an add-on setting and led to a recent approval (section 1.2.).

Treatment resistance

In the regulatory setting, TRD has been considered as failure of at least two different antidepressant agents deriving from the group(s) of commonly used as first line treatment (of the same or a different class) prescribed in adequate dosages for adequate duration and with adequate affirmation of treatment adherence (see previous version of the Depression Guideline EMA/CHMP/185423/2010 Rev. 2). Although the requirement of demonstration of failure of at least two antidepressants is still used for TRD trials, the inclusion of patients with one failed treatment at a maximum tolerated dose and adequate duration should not be excluded.

Retrospective assessment of partial response or lack of response could be a reasonable approach. Retrospective assessment of treatment failure should be primarily based on medical records of previous treatment and not on the patient's recollection of symptom improvement, which may be biased. Relevant data including use of and response to non-pharmacological interventions need to be carefully documented. Patients should be carefully screened for previous episodes of mania, hypomania or sub-threshold bipolarity and this would increase the accuracy of population selection, because it is desirable to have such population excluded.

Partial response

Sponsors should provide and justify clear criteria for partial response to antidepressant treatments (e.g. improvement of symptoms between $\geq 25\%$ and $< 50\%$).

4.4.1.1. Trial design in TRD and partial response

Short-term trials

For treatment resistance and partial response short-term randomised, parallel group studies will be needed, as in the case of general MDD population (section 4.3.2.). Depending on the mechanism of action the trial duration may vary considerably. Usually 4-6 weeks are likely to suffice for demonstration of short-term efficacy although typically substantially longer durations may be necessary according to the nature of the test treatment and patient population. In the case of RAADs it is recommended that Scientific advice is pursued prior to fixing the study design (section 4.3.2.3.). Pharmacokinetic or pharmacodynamic drug interactions relevant to the specific characteristics of the new compound should be studied prior to pivotal augmentation studies.

TRD

634 Monotherapy as well as add-on trials are acceptable trial designs in TRD.

635 a. Monotherapy

636 Since no medicinal product has been approved for monotherapy management of patients with TRD,
637 demonstration of efficacy should be superiority over placebo. Feasibility of study protocols including
638 ECT or rTMS as control arm seem to be limited.

639 b. Add-on treatment

640 Add-on treatments in TRD are a feasible approach. The test product is compared to placebo on a
641 background of a stable dose of an antidepressant therapy.

642 The choice of an add-on setting over a monotherapy setting should be justified as a rationale for the
643 product's mechanism of action in respect to the available alternatives is needed.

644 **Partial response**

645 Study designs should be conducted in an add-on setting to the antidepressant for which partial
646 response is shown. The comparator should be the antidepressant to which the new product is added
647 plus placebo in a superiority design.

648 **Maintenance of effect**

649 Depending on the mechanism of action and already established antidepressant efficacy, maintenance
650 of effect studies may be necessary (scientific advice is recommended). A randomised withdrawal study
651 is the design of choice to establish maintenance of effect of monotherapy and augmentation /add-on
652 treatment within the index episode. In the latter case responders to a combination treatment of a
653 known antidepressant and the new compound should be randomized to one of the following two
654 treatments: combination therapy of the test product and the known antidepressant versus the known
655 antidepressant plus placebo. A long-term extension trial with parallel design is not encouraged since it
656 will not answer the question whether long-term augmentation is really needed. If such study is chosen,
657 it needs justification and should be verified with scientific advice before starting it (section 4.3.2.2.)

658 **4.4.2. Specific domains in MDD**

659 Specific symptoms and domains within MDD, such as sleep disturbance, cognitive dysfunction, and
660 anhedonia, are reflected in the diagnostic criteria of the DSM-5. Impairment of specific domains or
661 symptom clusters in MDD (e.g. cognitive dysfunction) is of major importance to patients. The
662 development of targeted therapies to address symptom clusters which persist despite current
663 treatment and are mediated by known neurocircuitry are being proposed. **The efficacy in the targeted**
664 **(cluster of) symptoms should be specific for depression and not applicable to the same (clustered)**
665 **symptoms in other conditions. Thus, a pathophysiological justification for the claimed mechanisms of**
666 **action to treat specific symptoms will be required. If this approach is taken, trials designed to test the**
667 **specific hypothesis of efficacy in the context of a separate symptom, domain or dimension are required**
668 **as well as adequate endpoints. The patient population studied should not be artificially narrowed. The**
669 **effect of an antidepressant on the specific symptom or in a specific domain has to be demonstrated in**
670 **addition to and independently from the improvement of depressive symptoms using clinically**
671 **meaningful endpoints.**

672 **4.4.2.1. Improvement in cognitive function**

673 Cognitive dysfunction is considered a core feature in the psychopathology of MDD during both the
674 acute phase and the residual period and represents one of the symptoms for which a clinical need has
675 been identified. Sufficient evidence exists indicating that patients suffering from MDD exhibit deficits in

multiple domains of cognitive function, including learning and memory (verbal and nonverbal), attention, psychomotor speed, executive function, emotional processing and social cognition. Cognitive dysfunction may persist, despite resolution of the depressive symptoms in the acute phase. An effect on cognition may affect the time course of a depressive episode and this would be extremely beneficial and clinically relevant for patients.

If an effect on cognitive function in patients with MDD is claimed, specific effects on cognitive function need to be shown that could clearly be disentangled from the overall depressive symptoms. It depends on the robustness of the results whether a separate indication statement can be pursued or whether the data should rather be mentioned in section 5.1. of the SmPC. To support a separate claim for efficacy on cognitive aspects in patients with MDD or the improvement of cognitive impairment associated with MDD, ideally one specific and dedicated study should be performed to demonstrate such an effect.

There is a lack of consensus on best tools to accurately and efficiently assess cognition in clinical settings. No single test or series of tests have been established as the gold standard for the evaluation of cognitive function in MDD. As a general rule, tools for measuring/rating the improvement in cognitive dysfunction in MDD should be validated, pertinent in terms of realistically reflecting symptomatic severity, sufficiently sensitive to detect changes related to treatment and reliable (inter-rater; test/retest reliability). Applicants are encouraged to seek scientific advice before initiating an exploration of a claim in cognitive dysfunction in MDD.

It should be noted that demonstration of improvement in cognitive dysfunction and/or cognitive deficits will not be sufficient as the sole demonstration of efficacy for the indication of MDD.

4.4.3. Depression with specifiers

The DSM-5 includes a number of specifiers for depressive disorders with defined diagnostic features. If a claim for a sub-population as defined in a specifier is pursued, a dedicated trial with specific inclusion criteria and adequate endpoints is required.

Anxious distress

The frequent co-occurrence of depressive and anxious symptoms in MDD requires a specific approach. Anxiety symptoms may be a predominant part of MDD and depending on the criteria for the definitions can identify depression with anxious distress. From a regulatory perspective the population in which benefit/risk is demonstrated will be described in the label.

Post-partum depression

The specifier 'with peripartum onset' in the DSM-5 refers to depressive episode with an onset either during pregnancy or in the four weeks following delivery. Whether post-partum depression is distinct from major depressive episodes without peripartum onset is still a matter of debate, however based on identified differences in for example hormone contributions and symptomatology, a claim in post-partum depression should be supported by specifically designed studies in this sub-population.

4.5. Special Populations

4.5.1. Elderly patients

Depression in older people is not uncommon, but certainly not all older people with depressive symptoms will have MDD. In ICH E7 it is indicated that the efficacy and safety for the older people

population can be derived from the total database, provided that a sufficient number of elderly patients is included, unless there are specific reasons not to do this.

Studies have been conducted in older people, that could not distinguish between test product and placebo, even though the design of the studies and the dose of the test product were as expected, and efficacy of the product had already been shown in adults. This suggests a different pattern of response to first line antidepressants in the elderly population. In addition, depression with onset in the older age can be treatment refractory.

Moreover, extrapolation of the adult dose may be difficult due to pharmacokinetic properties of the product and/or to a different sensitivity in the older people for the pharmacodynamics of the product.

Therefore, not only efficacy, but defining a safe dose (range) in these patients is a main concern. Usually this should be addressed before licensing. Pharmacokinetic studies may support the choice of the dose and should be conducted.

Extrapolation of efficacy from adult studies to older patients is not encouraged. In principle, two approaches are possible. One is an analysis of the whole database, whereas the other would be to conduct specific trials in a specified patient population.

The first approach may be accepted as pivotal information for agents of known pharmacological classes, provided that a reasonable number of older people (representing sufficiently the growing population of the older people and hence ensuring generalizability) are included to allow a prospective subgroup analysis. As both efficacy and the optimal dose should be addressed, this may be difficult. Specific studies will be more informative and are preferred. Short term studies in older people will be sufficient, if full development in adults is available. These studies in older people should be adequately designed and powered to take into account the high drop-out rates and the high placebo response in older age group.

If a sufficient number of patients over 75 years of age are not included in the clinical development program, Phase IV studies in this patient group are considered necessary.

Primary endpoint should be the change from baseline in validated, age-appropriate rating scales for the core signs and symptoms of MDD. Response and remission should be defined in the protocol. Global and/or functional outcome measures should be estimated as secondary endpoints.

For new products with a new mechanism of action specific trials are usually needed. In case a claim for a product with a new mechanism of action is planned to be based on a pre-planned meta-analysis, this should be discussed with regulatory authorities when setting up the clinical development program.

4.5.2. Children and adolescents

Depressive disorders conforming to adult diagnostic criteria rarely present before the age of seven years. Hence, **the relevant age groups for juvenile depression are children (7-12 years of age) and adolescents (13-17 years of age).**

Early intervention and management are of major importance as depressive episodes may increase in severity and duration with recurrence and are associated with substantial morbidity, poor psychosocial outcome and risk of suicide.

Psychotherapeutic approaches are considered first line treatment in this population with MDD and psychopharmacologic approaches should normally be integrated in a stable psychosocial treatment setting. The clinical characteristics may vary somewhat according to age at presentation. **Children have a higher rate of physical somatic complaints including headaches and abdominal pain, while**

adolescents are more likely to complain of subjective feelings of low mood, and to have a higher rate of suicidal thoughts and self-blame.

There is inadequate evidence to conclude which type of treatment approach is most effective in preventing relapse or recurrence of depressive episodes in children and adolescents and there is still not enough evidence to support the implementation of depression prevention programmes.

Full extrapolation of adult efficacy and safety data is not considered appropriate. Short-term efficacy data should be generated in the paediatric population as in adults, separately for children 7 to < 12 years of age and for adolescents 12 years of age and older.

If a trial includes both children and adolescents, stratification for age group should be employed and the sample size calculation should allow for demonstration of efficacy in each age group independently.

If throughout the trials all subjects receive psychosocial interventions, this should be standardised wherever possible.

Efficacy in acute treatment should be demonstrated in at least one short-term placebo-controlled trial.

The study duration should be long enough to show statistically significant and clinically meaningful separation of active treatment from placebo. 4-6 weeks trials are usually recommended but this might need to be adapted depending on the mechanism of action (section 4.3.2.). If longer study durations are implemented, this should be justified in the protocol and must be balanced against the longer use of placebo control.

Primary endpoint should be the change from baseline in validated, age appropriate rating scales for the core signs and symptoms of MDD. Response and remission should be defined in the protocol. Global and/or functional outcome measures should be estimated as secondary endpoints.

Maintenance of effect and long-term efficacy studies may not be necessary in the paediatric population and extrapolation from adults could be acceptable, provided that robust evidence of short term-efficacy is available from both adults and the paediatric population (adolescents and children), and the effect size is comparable or analogous across trials.

Long-term safety data still need to be generated. Post-marketing long-term safety studies in children and adolescents could be structured to include also efficacy endpoints to support extrapolation of long-term efficacy.

4.5.3. Gender issues/differences

Serotonergic neurochemical responses which were differently affected in males and females have been observed in animal models, consequently causing sex-dependent effects in behaviour. In addition, certain animal species have exhibited a sexually dimorphic response to chronic antidepressant treatment.

There is higher prevalence of MDD in women. A number of publications have identified gender differences in patients with MDD. In women, the risk for suicide attempts is higher whereas the risk for suicide completion is lower compared to men. However, at present, these differences cannot be considered sufficient for specific recommendations for trial populations, which should be an accurate reflection of the patient population in clinical practice. Predefined analyses of gender specific groups are welcomed. Data should be presented specific for gender, age, race etc. to allow an estimate of potential differences.

4.6. Safety Evaluation

In general, the content of ICH E1 should be taken into consideration.

Identified adverse events (AEs), including serious AEs and AEs leading to withdrawal, should be characterised in relation to duration of treatment, dosage, recovery time, age, frailty and other

relevant variables. Adverse event scales should be standardised for use in studies with psychotropic drugs (e.g. UKU scale). Clinical observations should be supplemented by appropriate laboratory tests and cardiac recordings (e.g. ECG). AE rates should be presented for the test treatment, placebo and active comparators.

As treatment durations including the long term open label trials will generally be longer for the test treatment as compared to other treatments (e.g. placebo), the data should be presented in a suitable way for comparisons of event rates.

Special efforts should be made to assess potential AE reactions that are characteristics of the class of drugs being investigated in view of actions on specific receptor sites. Particular attention should be paid to anti-dopaminergic, anti-cholinergic or cholinergic, anti-histaminergic, serotonergic and α -adrenergic, and to glutamatergic or anti-GABAergic AEs, if relevant.

4.6.1. Specific adverse events to be monitored

4.6.1.1. Psychiatric adverse events

Psychiatric adverse events typically represent a large proportion of the AEs reported in trials in MDD patients. These events may be related to the disorder itself as well as to the study medication. These may include but are not limited to anxiety, dysphoria, agitation, aggression, insomnia, dissociation, hallucinations, confusion (see also section 4.6.1.3.). In order to explore the risk of an adverse effect on the severity of the disorder being treated, the proportion of patients deteriorating during treatment should be documented using the primary efficacy measure.

4.6.1.2. Adverse effects on cognitive functioning

A detrimental effect on cognition should be monitored using validated rating scales, which may be identical to those used to support an efficacy claim. Effects on cognition, reaction time, driving and severity of sedation should also be studied. In the adolescent population specific issues such as memory, learning, school performance, etc. should be studied in relation to both the safety and efficacy perspective.

4.6.1.3. Overdose and suicide

Depending on the mechanism of action risks and effects of overdose should be studied particularly with regard to serotonin-syndrome, QT-prolongation and delirium.

The potential for the test product to precipitate suicidal thoughts and behaviour should be actively measured in all age groups using validated rating scales (e.g. InterSePT Scale for Suicidal Thinking, Columbia Suicidality Severity Rating Scale (C-SSRS), the SIBQ (Suicidal Ideation and Behaviour Questionnaire) or other validated instruments). Rates of suicidal events (from suicidal ideation to completed suicide) should be presented and narrative summaries of suicidal patient statements or behaviours should be provided.

4.6.1.4. Metabolic risk factors

The effects on weight, glucose metabolism and lipid metabolism should be actively measured using standard laboratory measures. The metabolic profile of the test product should be thoroughly characterised in comparison with placebo and active comparator(s).

4.6.1.5. Haematological adverse events

Special attention should be paid to incidence of neutropenia, agranulocytosis and aplastic anaemia.

4.6.1.6. Endocrinological adverse events

The effects on sexual functioning, galactorrhoea and gynaecomastia should be evaluated. Investigation of neuro-endocrinological parameters relating to prolactin is necessary. In the adolescent population effects on growth and sexual maturation require specific attention and should be closely monitored.

4.6.1.7. Cardiovascular adverse events

Due to the known cardiovascular effects associated cardiac adverse events should be actively monitored. Reported adverse events that might represent orthostatic hypotension or arrhythmia (including syncope, loss of consciousness, etc.) should be presented where relevant. The effect on QT-interval prolongation should be investigated in accordance with the ICH E14 guideline.

4.6.1.8. Sexual dysfunction

Special attention should be paid to the effect on sexual function and libido.

4.6.1.9. Extrapyramidal symptoms (EPS)

There is concern that patients with affective disorders show a higher sensitivity to suffer from acute extrapyramidal side effects and a higher incidence of tardive dyskinesias compared to patients with schizophrenia. Therefore, if antipsychotics are used for augmentation or as treatment option in treatment resistant depressive patients, rates of extrapyramidal symptoms should be presented. In addition, the extent and severity of EPS should be actively measured using validated and specifically designed rating scales. Dose – response relationships of EPS should be explored. During the wash out phase prior to acute studies, possible tardive EPS should be measured to distinguish this from acute EPS due to the test treatment.

Tardive dyskinesia occurs late in treatment and is reported for both atypical and typical antipsychotics.

4.6.1.10. Serotonin syndrome / Neuroleptic malignant syndrome

Serotonin syndrome (SS) can be caused by excessive serotonergic agonism in central and peripheral nervous system serotonergic receptors and has been described for many antidepressants. The clinical symptoms include neuromuscular hyperactivity, autonomic hyperactivity and altered mental status.

Neuroleptic malignant syndrome (NMS) consists of similar clinical symptoms and has been reported for all antipsychotics.

4.6.1.11. Rebound / withdrawal phenomena / dependence

When pharmacological treatment is stopped, rebound and/or withdrawal phenomena may occur. Trials should be designed in such a way, that these phenomena can be studied. In some of the short-term and long-term clinical trials, treatment should be stopped abruptly and patients should be followed for a suitable duration, in other studies careful tapering off might be more appropriate, depending on the mechanism of action of the compound. Occurrence of rebound and/or withdrawal phenomena should be evaluated at the appropriate time.

Animal studies will be needed to investigate the possibility of dependence in new classes of compounds or when there is an indication that dependence may occur.

Depending on the results of these studies further studies in humans may be needed.

4.6.1.12. Long-term safety

Since a depressive episode can have a duration of up to 2 years, the total clinical experience should generally include data on a large and representative group of patients in line with the guideline on population exposure of at least 12 months.

4.6.1.13. Elderly patients

Certain adverse events such as anticholinergic effects, delirium, sedative effects, cardiovascular and hypotensive effects, dizziness, falls, effect on food intake and functional decline, have been observed in elderly patients treated with certain antidepressants and these should be monitored in the trials designed for elderly patients.

4.6.1.14. Children and adolescence

Rather than relying on spontaneous AE reporting, potential treatment-emergent adverse events such as somnolence, sexual disturbances, weight gain, affective symptoms and suicidality, discontinuation/rebound symptoms, etc. should be clearly defined and actively monitored. Validated questionnaires/scales/tests should be used for the assessment of adverse events.

Long-term effects on learning, development, growth and sexual function may be studied post-marketing, but appropriate protocols should be available when the use in children is applied for.

5. References

- ACNP releases final task force report on antidepressants and suicidality among adolescents. Psychiatr Serv, 2006. **57**(2): p. 283.
- Abi-Dargham A, Moeller SJ, Ali F et al. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry 2023; 22:236-262.
- Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 2020, **34**: 155-166.
- Akiskal, H.S. and F. Benazzi, Does the FDA proposed list of possible correlates of suicidality associated with antidepressants apply to an adult private practice population? J Affect Disord, 2006, **94**(1-3): p. 105-10.
- Alexopoulos G.S: "Chapter 5. Assessment scales for geriatric patients" in the Book "Guide to Assessment Scales in Major Depressive Disorder", edited by George Alexopoulos, Siegfried Kasper, Hans-Jürgen Möller and Carmen Moreno, published by Springer International Publishing Switzerland 2014
- Ambrosi E. et al., Insula and amygdala resting-state functional connectivity differentiate bipolar from unipolar depression, Acta Psychiatr Scand. 2017 Jul; **136**(1):129-139. Mar 28. doi: 10.1111/acps.12724. [Epub ahead of print]
- American Psychiatric Association 2013 "Highlights of Changes from DSM-IV-TR to DSM-5"
- Amsterdam, J.D. and M. Hornig-Rohan, Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am, 1996. **19**(2): p. 371-86.
- Ananth, J., Treatment-resistant depression. Psychother Psychosom, 1998. **67**(2): p. 61-70.

- Anderson M. I. Chapter 4 Principles of therapy eds. E. S. Friedman and I. M. Anderson, Handbook of Depression, 2014, DOI: 10.1007/978-1-907673-79-5_4, Springer Healthcare 2014
- Baer, L., Ball, S., Sparks, J., Raskin, J., Dubé, S., Ferguson, M., & Fava, M. (2014). Further evidence for the reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ). *Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists*, **26**(4): 270–280
- Bailey, K.P., Treating treatment-resistant depression. Whether to switch, augment, or combine therapies. *J Psychosoc Nurs Ment Health Serv*, 2003. **41**(6): p. 14-20.
- Baldwin, R.C. and S. Simpson, Treatment resistant depression in the elderly: a review of its conceptualisation, management and relationship to organic brain disease. *J Affect Disord*, 1997. **46**(3): p. 163-73.
- Bannan, N., Multimodal therapy of treatment resistant depression: a study and analysis. *Int J Psychiatry Med*, 2005. **35**(1): p. 27-39.
- Barbee, J.G. and Jamhour, N.J., Lamotrigine as an augmentation agent in treatment-resistant depression. *J Clin Psychiatry*, 2002. **63**(8): p. 737-41.
- Barbee, J.G., Conrad, E.J. and Jamhour, N.J., Aripiprazole augmentation in treatment-resistant depression. *Ann Clin Psychiatry*, 2004. **16**(4): p. 189-94.
- Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR. The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms. *J Psychopharmacol* 2016; **30**: 1279–95.
- Berlim, M.T., Fleck, M.P. and Turecki, G., Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. *Ann Med*, 2008. **40**(2): p. 149-59.
- Berlim, M.T. and Turecki, G., Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. *Can J Psychiatry*, 2007. **52**(1): p. 46-54.
- Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients with Alcohol Use Disorder: A Randomized Clinical Trial. *JAMA Psychiatry* 2022; **79**:953-962.
- Bowden, C.L., Treatment strategies for bipolar depression. *J Clin Psychiatry*, 2010. **71**(5): p. e10.
- Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. *J Psychopharmacol*. 2022; **36**:1100-1117.
- Brent, D.A. and B. Birmaher, Treatment-resistant depression in adolescents: recognition and management. *Child Adolesc Psychiatr Clin N Am*, 2006. **15**(4): p. 1015-34, x.
- Bridge J.A., Iyengar S. and Salary C.B., Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials *JAMA*. 2007; **297**(15):1683-1696. doi:10.1001/jama.297.15.1683,
- Bryleva EY and Brundin L, Kynurenine pathway metabolites and suicidality, *Neuropharmacology*. 2017 Jan; **112**(Pt B):324-330. doi: 10.1016/j.neuropharm.2016.01.034. Epub 2016 Jan 26.
- Bschor, T., Therapy-resistant depression. *Expert Rev Neurother*, 2010. **10**(1): p. 77-86.
- Busch, S.H., et al., Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? *Psychiatr Serv*, 2010. **61**(1): p. 11-6.
- Butlen-Ducuing, F., Balkowiec-Iskra, E., Dalla, C., Slattery, D. A., Ferretti, M. T., Kokras, N., Balabanov, P., De Vries, C., Mellino, S., & Santucci Chadha, A. (2021). Implications of sex-related differences in central nervous system disorders for drug research and development. *Nature reviews. Drug discovery*, **20**(12), 881–882. <https://doi.org/10.1038/d41573-021-00115-6>. PMID: 34226696

- Butler M, Jelen L, Rucker J. Expectancy in placebo-controlled trials of psychedelics: if so, so what? *Psychopharmacology* 2022; **239**: 3047–3055.
- Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, Kaelen M. Psychedelics and the essential importance of context. *J Psychopharmacol.* 2018; **32**:725-731.
- Carvalho, A.F., J.R. Machado, and J.L. Cavalcante, Augmentation strategies for treatment-resistant depression. *Curr Opin Psychiatry*, 2009. **22**(1): p. 7-12.
- Cipriani, A., M. Dieterich, and C. Barbui, Review: atypical antipsychotics are effective adjuncts for treatment resistant depression but increase discontinuation due to adverse effects. *Evid Based Ment Health*, 2008. **11**(1): p. 14.
- Colasanti, V., et al., Tests for the evaluation of depression in the elderly: a systematic review. *Arch Gerontol Geriatr*, 2010. **50**(2): p. 227-30.
- Costa M.V., Diniz M.F., Nascimento K.K., "Accuracy of three depression screening scales to diagnose major depressive episodes in older adults without neurocognitive disorders", *Rev Bras Psiquiatr.* 2016 Apr-Jun; **38**(2):154-6. doi: 10.1590/1516-4446-2015-1818,
- Crumpacker, D.W., Suicidality and antidepressants in the elderly. *Proc (Bayl Univ Med Cent)*, 2008. **21**(4): p. 373-7.
- Daban, C., et al., Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. *J Affect Disord*, 2008, **110**(1-2): p. 1-15.
- Dalla C, et al., Sex differences in animal models of depression and antidepressant response, *Basic Clin Pharmacol Toxicol.* 2010 Mar; **106**(3):226-33. doi: 10.1111/j.1742-7843.2009.00516.x. Epub 2009 Dec 30.
- Dalla, C., Pavlidi, P., Sakellidou, D. G., Grammatikopoulou, T., & Kokras, N. (2022). Sex Differences in Blood-Brain Barrier Transport of Psychotropic Drugs. *Frontiers in behavioral neuroscience*, **16**, 844916, PMID: 35677576.
- Davey, C.G., M. Yucel, and N.B. Allen, The emergence of depression in adolescence: development of the prefrontal cortex and the representation of reward. *Neurosci Biobehav Rev*, 2008, **32**(1): p. 1-19.
- Dudley, M., R. Goldney, and D. Hadzi-Pavlovic, Are adolescents dying by suicide taking SSRI antidepressants? A review of observational studies. *Australas Psychiatry*, 2010, **18**(3): p. 242-5.
- Dudley, M., et al., New-generation antidepressants, suicide and depressed adolescents: how should clinicians respond to changing evidence? *Aust N Z J Psychiatry*, 2008, **42**(6): p. 456-66.
- European Medicines Agency. Spravato (esketamine). <https://www.ema.europa.eu/en/medicines/human/EPAR/spravato> (accessed Feb 1, 2023).
- European Medicines Agency. Parallel joint scientific consultation with regulators and health technology assessment bodies. 2023. <https://www.ema.europa.eu/en/human-regulatory/research-development/scientificadvice-protocol-assistance/parallel-joint-scientific-consultation-regulatorshealth-technology-assessment-bodies> (accessed Feb 1, 2023).
- European Medicines Agency. Scientific advice and protocol assistance. 2023. <https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-advice-protocol-assistance> (accessed Feb 1, 2023).
- European Medicines Agency. Clinical investigation of medicinal products in the treatment of depression—scientific guideline. 2023. <https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatmentdepression-scientific-guideline> (accessed Feb 1, 2023).
- European Medicines Agency. Clinical Trials Information System. 2023. <https://www.ema.europa.eu/en/human-regulatory/research-development/clinicaltrials/clinical-trials-information-system> (accessed Feb 1, 2023).

- Fava, M. Diagnosis and definition of treatment-resistant depression. *Biol Psychiatry* **53**, 649- 59 (2003).
- Fava M, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. *Psychol Med* 2004; **34**(7):1299-1308.
- Fava, M., Iosifescu, D. V., Pedrelli, P., & Baer, L. (2009). Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. *Psychotherapy & Psychosomatics*, **78**(2): 91-97.
- Fekadu, A., et al., A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. *J Clin Psychiatry*, 2009. **70**(2): p. 177-84.
- Fornaro, M. and P. Giosue, Current nosology of treatment resistant depression: a controversy resistant to revision. *Clin Pract Epidemiol Ment Health*, 2010. **6**: p. 20-4.
- Fournier, J.C., et al., Antidepressant drug effects and depression severity: a patient-level meta-analysis. *JAMA*, 2010. **303**(1): p. 47-53.
- Garriga, M., Sol, E., Gonzalez-Pinto, A et al., Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial, *European Neuropsychopharmacology* Volume **27**, Issue 10, October 2017, Pages 959-969,
- Gartlehner G et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis, *Ann Intern Med*. 2011 Dec 6; **155**(11):772-85. doi: 10.7326/0003-4819-155-11-201112060-00009.
- Geddes JR et al., Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review, *Lancet* 2003 Feb 22; **361**(9358):653-61.
- Geddes JR Relapse prevention and antidepressants, *Lancet*. 2003 Jun 21; **361**(9375), Author's reply 2159.
- Gijsen-de Wied C, Stoyanova V, Yu Y et al. The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma, *Eur Neuropsychopharmacol*. 2012 Nov; **22**(11):804-11. doi: 10.1016/j.euroneuro.2012.03.007. Epub 2012 Jun 15
- Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. *N Engl J Med* 2022; 387:1637-1648 Gotlib, I.H. and J. Joormann, Cognition and depression: current status and future directions. *Annu Rev Clin Psychol*, 2010. **6**: p. 285-312.
- Goya-Maldonado R et al., Differentiating unipolar and bipolar depression by alterations in large-scale brain networks, *Hum Brain Mapp*. 2016 Feb; **37**(2):808-18. doi: 10.1002/hbm.23070. Epub 2015 Nov 27.
- Greer, T.L., B.T. Kurian, and M.H. Trivedi, Defining and measuring functional recovery from depression. *CNS Drugs*, 2010, **24**(4): p. 267-84.
- Grieco SF, Castrén E, Knudsen GM, et al. Psychedelics and Neural Plasticity: Therapeutic Implications. *J Neurosci* 2022; **42**: 8439-8449.
- Grunze, H.C., Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? *CNS Spectr*, 2008. **13**(9): p.790-5.
- Guy M. Goodwin, F.Med.Sci., Scott T. Aaronson, M.D., Oscar Alvarez, M.R.C.Psych. and al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. *N Engl J Med* Nov 2022; **387**:1637-1648
- Harmer, C.J., Cowen, P.J. and Goodwin, G.M., Efficacy markers in depression. *J Psychopharmacol*, 2011, Sep; **25**(9):1148-58. doi: 10.1177/0269881110367722..

- Hegerl, U., Antidepressants and suicidality. *Eur Arch Psychiatry Clin Neurosci*, 2006. **256**(4): p. 199-200.
- Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. *Cochrane Database of Systematic Reviews* 2012, Nov 14; **11**(11):CD004851. doi: 10.1002/14651858.CD004851.pub3.
- Hirschfeld RM, Differential diagnosis of bipolar disorder and major depressive disorder, *J Affect Disord*. 2014 Dec; **169** Suppl 1: S12-6. doi: 10.1016/S0165-0327(14)70004-7.
- Holroyd, M.D., Clayton, A.H. MD, "Measuring Depression in the Elderly: Which Scale is Best?" *J Medscape General Medicine*. 2000; **2**(4).
- Holzel, L., et al., Risk factors for chronic depression - A systematic review. *J Affect Disord*, 2011, Mar; **129**(1-3):1-13. doi: 10.1016/j.jad.2010.03.025.
- Holze F, Gasser P, Müller F, et al. Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. *Biol Psychiatry* 2023; **93**: 215-223.
- Horton DM, Morrison B, Schmidt J. Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy. *Am J Psychother*. 2021; **74** :140-149.
- International Narcotics Control Board. Green List—list of psychotropic substances under international control. 2022. <https://www.incb.org/incb/en/psychotropics/green-list.html> (accessed Feb 7, 2023).
- Isacsson, G., et al., Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995-2005. *Acta Psychiatr Scand*, 2009. **120**(1): p. 37-44.
- Iverson, G. L. (2007). British Columbia Cognitive Complaints Inventory (BC-CCI). Vancouver: Self-Published. Available at: <https://workingwithdepression.psychiatry.ubc.ca/leaps/the-british-columbia-cognitive-complaints-inventory-bc-cci/> (accessed March 31, 2023).
- Iverson, G. L. & Lam, R. W. (2013). Rapid screening for perceived cognitive impairment in major depressive disorder. *Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists*, **25**(2): 135–140
- Jeon HJ, et al. Gender Differences in Somatic Symptoms and Current Suicidal Risk in Outpatients with Major Depressive Disorder, *Psychiatry Investig*. 2016 Nov;13(6):609-615. Epub 2016 Nov 24.
- Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. *Am J Drug Alcohol Abuse* 2017; **43** :55-60.
- Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. *Am J Drug Alcohol Abuse* 2017; **43**: 55–60.
- Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. *J Psychopharmacol* 2008; **22**: 603–20.
- Kasper S., Lemming O.M., de Swart H., "Escitalopram in the long-term treatment of major depressive disorder in elderly patients", *Neuropsychobiology*. 2006; 54(3):152-9. Epub 2007 Jan 17
- Kennedy, S.H. and P. Giacobbe, Treatment resistant depression--advances in somatic therapies. *Ann Clin Psychiatry*, 2007. **19**(4): p. 279-87.
- Khan A, and Brown WA, Antidepressants versus placebo in major depression: an overview, *World Psychiatry*. 2015 Oct; **14**(3):294-300. doi: 10.1002/wps.20241.
- Khin NA et al., Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications, *J Clin Psychiatry*. 2011 Apr;72(4):464-72. doi: 10.4088/JCP.10m06191.
- Kirsch I, Antidepressants and the Placebo Effect, *Z Psychol*. 2014; **222**(3):128-134.

Kirsch I et al., Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration, *PLoS Med.* 2008 Feb; **5**(2): e45. doi: 10.1371/journal.pmed.0050045.

Kokras N and Dalla C, Preclinical sex differences in depression and antidepressant response: Implications for clinical research, *J Neurosci Res.* 2017 Jan 2; 95(1-2):731-736. doi: 10.1002/jnr.23861.

Kokras, N., Hodes, G. E., Bangasser, D. A., & Dalla, C. (2019). Sex differences in the hypothalamic–pituitary–adrenal axis: An obstacle to antidepressant drug development? *British Journal of Pharmacology*, **176**(21), 4090-4106. DOI: 10.1111/bph.14710 PMID: 31093959

Krishnan, V., Nestler, E.J. Linking molecules to mood: new insight into the biology of depression. *Am J Psychiatry.* 2010. **167** (11): p. 1305-1320.

Kroenke, K., Review: GPs accurately diagnose about 50% of patients with depression and accurately classify 81% of nondepressed patients. *Ann Intern Med*, 2010. **152**(8): p. JC4-13.

Krystal J.H., Sanacora G., Duman R.S., "Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond", *Biol Psychiatry.* 2013 Jun 15; **73**(12): 1133–1141, doi: 10.1016/j.biopsych.2013.03.026, PMCID: PMC3671489, NIHMSID: NIHMS466839, PMID: 23726151

Lam R.W. Subjective measures of cognitive dysfunction in major depressive disorder, ed McIntyre R.S. *Cognitive Impairment in Major Depressive Disorder, Clinical Relevance, Biological Substrates, and Treatment Opportunities*, Book, Cambridge University Press, May 2016.

Lam, R.W., et al., Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. *Can J Psychiatry*, 2008. **53**(9): p. 621-31.

Lam RW, Michalak EE, Swinson RP. *Assessment Scales in Depression and Anxiety*. London and New York: Taylor & Francis; 2005.

Lam, R. W., Saragoussi, D., Danchenko, N., Rive, B., Lamy, F. X., & Brevig, T. (2013). Psychometric Validation of Perceived Deficits Questionnaire – Depression (PDQ–D) in patients with major depressive disorder (MDD). *Value in Health*, **16**(7): A330

Lambkin M. Prescription psychedelics: the road from FDA approval to clinical practice. *Am J Med* 2022; **135**: 15–16.

Leon, A.C., The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. *Am J Psychiatry*, 2007. **164**(12): p. 1786-9.

Leuchter, A.F. et al. Biomarkers to predict antidepressant response. *Curr Psychiatry Rep*, 2010, **12**: p.553-562

Lewandowski R.E., Acri M.C., Hoagwood K.E., et al., Evidence for the Management of Adolescent Depression, *PEDIATRICS* Volume **132**, Number 4, October 2013 e996-e1009,

Lichtenberg P.A., Marcopulos B.A., Steiner D.A., Tabscott J.A. et al., "Comparison of the Hamilton Depression Rating Scale and the Geriatric Depression Scale: detection of depression in dementia patients", *Psychol Rep.* 1992 Apr;70(2):515-21,

Madras BK Psilocybin in Treatment-Resistant Depression. *N Engl J Med* 2022; **387**: 1708-1709

Mansfield, P.R., M.K. Raven, and J.N. Jureidini, Depressed youth, suicidality and antidepressants. *Med J Aust*, 2005. **183**(5): p. 275; author reply 276.

Marazziti, D., et al., Cognitive impairment in major depression. *Eur J Pharmacol*, 2010. **626**(1): p. 83-6.

McClintock, S.M., et al., Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis. *Neuropsychology*, 2010. **24**(1): p. 9-34.

McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. *Nat Rev Drug Discov.* 2022 Jun; **21**(6):463-473. doi: 10.1038/s41573-022-00421-7.

Meltzer-Brody S, Davidson JR. Completeness of response and quality of life in mood and anxiety disorders. *Depress Anxiety* 2000; **12**(Suppl 1):95-101.

Moller, H.J., Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. *World J Biol Psychiatry*, 2009. **10**(3): p. 180-95.

Moller H-J. Observer Rating Scales, eds G. Alexopoulos et al., *Guide to Assessment Scales in Major Depressive Disorder*, Book, Springer International Publishing Switzerland 2014, DOI 10.1007/978-3-319-04627-3_1

Mossner R. et al., Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression, *World J Biol Psychiatry*. 2007; **8**(3):141-74.

Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. *Expert Rev Clin Pharmacol* 2021; **14**: 1133–52.

Nakajima, S., et al., Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. *Prog Neuropsychopharmacol Biol Psychiatry*, 2010. **34**(2): p. 259-64.

National Institute (NICE). Depression in children and young people: identification and management, Clinical guideline [CG28] Published: 26 September 2005, replaced by NICE guideline [NG134] Published: 25 June 2019.

Nayak S, Johnson MW, Psychedelics and Psychotherapy. *Pharmacopsychiatry* 2021; **54** :167-175.

Nayak SM, Gukasyan N, Barrett FS. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. *Pharmacopsychiatry* 2021; **54**: 240–245.

Nemeroff, C.B., Prevalence and management of treatment-resistant depression. *J Clin Psychiatry*, 2007. **68** Suppl 8: p. 17-25.

Nierenberg AA and DeCecco LM, Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression, *J Clin Psychiatry*. 2001; **62** Suppl 16:5-9.

Nivoli, A.M., et al., New treatment guidelines for acute bipolar depression: A systematic review. *J Affect Disord*, 2011, Mar; **129**(1-3):14-26. doi: 10.1016/j.jad.2010.05.018.

Nutt DJ, King LA, Phillips LD; Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. *Lancet*. 2010 Nov 6; **376** (9752):1558-65.

OECD/European Union. Health at a Glance: Europe 2018: State of Health in the EU Cycle, OECD, 2018.

Organisation for Economic Co-operation and Development, European Union. Health at a glance: Europe 2018: state of health in the EU cycle. Paris: OECD Publishing, 2018.

Organisation for Economic Co-operation and Development. A new benchmark for mental health systems: tackling the social and economic costs of mental ill-health. OECD Health Policy Studies. Paris: OECD Publishing, 2021.

Papakostas G.I. and Fava M. Chapter 1: Major Depressive Disorder and Treatment-Resistant Depression, *Pharmacotherapy for Depression and Treatment-Resistant Depression*, Book 2010, World Scientific Publishing Co. Pte. Ltd.,

Park RJ Clinical guidelines for depressive disorders in childhood and adolescence. *Eur Child Adolesc Psychiatry*. 2000 Sep; **9**(3):147-61

Pettersson A., Bengtsson Boström K., Gustavsson P. and Ekselius L., Which instruments to support diagnosis of depression have sufficient accuracy? A systematic review, *Nordic Journal of Psychiatry*, 2015, **69**:7, 497-508, DOI: 10.3109/08039488.2015.1008568

Philip, N.S., et al., Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. *Expert Opin Pharmacother*, 2010, **11**(5): p. 709-22.

Ragguett RM, et al., Assessing and measuring cognitive function in major depressive disorder, *Evid Based Ment Health*. 2016 Nov; **19**(4):106-109. doi: 10.1136/eb-2016-102456. Epub 2016 Oct 8.

Reeves, H., et al., Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. *J Clin Psychiatry*, 2008, **69**(8): p. 1228-336.

Reid, S. and C. Barbui, Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. *BMJ*, 2010, 340: p. c1468.

Reiff CM, Richman EE, Nemeroff CB, et al; Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. Psychedelics and psychedelic-assisted psychotherapy. *Focus (Am Psychiatr Publ)* 2021; **19**: 95–115.

Reus GZ, et al., Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies, *J Psychiatr Res*. 2015 Sep; **68**: 316-28. doi: 10.1016/j.jpsychires.2015.05.007. Epub 2015 May 19.

Robinson O.J., Roiser J.P., and Sahakian B.J. Hot and cold cognition in major depressive disorder, ed McIntyre R.S. *Cognitive Impairment in Major Depressive Disorder, Clinical Relevance, Biological Substrates, and Treatment Opportunities*, Book, Cambridge University Press, May 2016.

Roiser JP and Sahakian BJ., Hot and cold cognition in depression, *CNS Spectr*. 2013 Jun; **18**(3):139-49. doi: 10.1017/S1092852913000072. Epub 2013 Mar 12.

Rootman JM, Kiraga M, Kryskow P, Harvey K, Stamets P, Santos-Brault E, Kuypers KPC, Walsh Z. Author Correction: Psilocybin microdoses demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. *Sci Rep*. 2022 Jul 28; **12**(1):12925.

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry*. 2006 Nov; **163**(11):1905-17. doi: 10.1176/ajp.2006.163.11.1905. PMID: 17074942.

Schuch JJ, et al., Gender differences in major depressive disorder: results from the Netherlands study of depression and anxiety, *J Affect Disord*. 2014 Mar; **156**: 156-63. doi: 10.1016/j.jad.2013.12.011. Epub 2013 Dec 17.

Seemuller, F., et al., The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. *Int J Neuropsychopharmacol*, 2009, **12**(2): p. 181-9.

Sforzini, L. et al., A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. *Mol Psychiatry*, 2022, **27**(3):p.1286-1299

Shorey S, Ng ED, Wong CHJ. Global prevalence of depression and elevated depressive symptoms among adolescents: A systematic review and meta-analysis. *Br J Clin Psychol*. 2022 Jun; **61**(2):287-305. doi: 10.1111/bjc.12333. Epub 2021 Sep 26. PMID: 34569066.

Shyn, S.I. and S.P. Hamilton, The genetics of major depression: moving beyond the monoamine hypothesis. *Psychiatr Clin North Am*, 2010. **33**(1): p. 125-40.

Souery, D., Papakostas, G.I. & Trivedi, M.H. Treatment-resistant depression. *J Clin Psychiatry*, 2006, **67** Suppl 6, 16-22 (2006).

Steven F. Grieco, Eero Castrén, Gitte M. Knudsen, Alex C. Kwan, David E. Olson, Yi Zuo, Todd C. Holmes, Xiangmin Xu. Psychedelics and Neural Plasticity: Therapeutic Implications. *Journal of Neuroscience* 9 November 2022, **42** (45) 8439-8449.

Stone, M., et al., Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. *BMJ*, 2009. **339**: p. b2880.

Thase, M.E. & Rush, A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. *J Clin Psychiatry* **58** Suppl 13, 23-9 (1997),

Trivedi MH, Fava M, Wisniewski, et al., Medication augmentation after the failure of SSRIs for depression, *N Engl J Med*. 2006 Mar 23; **354**(12):1243-52

Tsapakis E.M., Soldani F., Tondo L. et al., Efficacy of antidepressants in juvenile depression: meta-analysis, *The British Journal of Psychiatry* (2008) **193**, 10–17. doi: 10.1192/bjp.bp.106.031088

Tseng MM et al., Comparison of associated features and drug treatment between co-occurring unipolar and bipolar disorders in depressed eating disorder patients, *BMC Psychiatry*. 2017 Feb 27; **17**(1):81. doi: 10.1186/s12888-017-1243-0.

Tullis, Paul. The rise of psychedelic psychiatry. *Nature* **589**, 506-509 (2021)

Vizeli P, Straumann I, Holze F, et al. Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. *Sci Rep* 2021; **11**:10851.

Vollenweider FX, Vontobel P, Hell D et al. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [¹¹C]raclopride. *Neuropsychopharmacology* 1999; **20**: 424-433.

WHO, 2023 Depression Fact Sheet, accessed 11.August 2023

Wijeratne, C. and P. Sachdev, Treatment-resistant depression: critique of current approaches. *Aust N Z J Psychiatry*, 2008. **42**(9): p. 751-62.

Wisner, K.L., E.L. Moses-Kolko, and D.K. Sit, Postpartum depression: a disorder in search of a definition. *Arch Womens Ment Health*, 2010, **13**(1): p. 37-40.

Xu Y., Bai S.J., Lan X.Y., et al. Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability, *Braz J Med Biol Res* vol. **49** no.6 Ribeirao Preto 2016 Epub May 24, 2016, <http://dx.doi.org/10.1590/1414-431X20164806>

Yesavage J. A., and Sheikh J.I. (1986) 9/Geriatric Depression Scale (GDS), *Clinical Gerontologist*, **5**:1-2, 165-173, DOI: 10.1300/J018v05n01_09

Definitions

Relapse:

Relapse is defined as re-emergence of depressive signs and/or symptoms within the index episode independent from medication status. It usually indicates that treatment duration was too short or dosage of treatment was insufficient.

Recurrence:

Recurrence is defined as a re-emergence of depressive symptoms after a time without or nearly without symptoms (remission) and without medication. It is seen as the start of a new episode.

Rebound and Withdrawal:

1420 Rebound and withdrawal are phenomena, which are due to tolerance/dependence on and/or
1421 discontinuation of the medicinal product. Rebound is defined as an increase of symptoms immediately
1422 after treatment is stopped, whereas withdrawal is the development of symptoms different from the
1423 original ones.

1424 **Abbreviations**

1425 AEs: Adverse Events

1426 BD: Bipolar disorder

1427 CHMP: Committee for Medicinal Products for Human Use

1428 DSM-5: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition

1429 ECG: Electrocardiogram

1430 EMA: European Medicines Agency

1431 EPS: Extrapyramidal symptoms

1432 GABA: Gamma-Aminobutyric acid

1433 GAD: Generalised Anxiety Disorder

1434 ICD-11: International Statistical Classification of Diseases and Related Health Problems, 11th Revision

1435 ICH: International Conference on Harmonisation

1436 MDD: Major Depressive Disorder

1437 NMS: Neuroleptic Malignant Syndrome

1438 RAAD: Rapid acting antidepressant

1439 SmPC: Summary of Product Characteristics

1440 SSRI: Selective serotonin reuptake inhibitors

1441 TRD: Treatment Resistant Depression